Why the study?
Does candesartan prevent stress-induced changes in brain AT1/AT2 receptor binding and tyrosine hydroxylase transcription in spontaneously hypertensive rats?
Does candesartan prevent stress-induced changes in brain AT1/AT2 receptor binding and tyrosine hydroxylase transcription in spontaneously hypertensive rats?
Oral candesartan blocks brain AT1 receptors and prevents stress-induced central stimulation of tyrosine hydroxylase transcription in spontaneously hypertensive rats, suggesting potential therapeutic use in stress-related disorders.
Candesartan effects on stress pathways remain preclinical; leaves open whether AT1 blockade translates to human stress-related disorders.
Spontaneously hypertensive rats, a stress-sensitive strain, were pretreated orally for 14 days with the AT(1) receptor antagonist candesartan before submission to 2 h of cold-restraint stress. In non-treated rats, stress decreased AT(1) receptor binding in the median eminence and basolateral amygdala, increased AT(2) receptor binding in the medial subnucleus of the inferior olive, decreased AT(2) binding in the ventrolateral thalamic nucleus and increased tyrosine hydroxylase mRNA level in the locus coeruleus. In non-stressed rats, AT(1) receptor blockade reduced AT(1) receptor binding in all areas studied and enhanced AT(2) receptor binding in the medial subnucleus of the inferior olive. Candesartan pretreatment produced a similar decrease in brain AT(1) binding after stress, and prevented the stress-induced AT(2) receptor binding decrease in the ventrolateral thalamic nucleus. In the locus coeruleus and adrenal medulla, AT(1) blockade abolished the stress-induced increase in tyrosine hydroxylase mRNA level. Our results demonstrate that oral administration of candesartan effectively blocked brain AT(1) receptors, selectively increased central AT(2) receptor expression and prevented the stress-induced central stimulation of tyrosine hydroxylase transcription. The present results support a role of brain AT(1) and AT(2) receptors in the regulation of the stress response, and the hypothesis that AT(1) receptor antagonists may be considered as potential therapeutic compounds in stress related disorders in addition to their anti-hypertensive properties.
No takes yet. Share an insight, caveat, or question.
Bregonzio et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: